Rigel Pharmaceuticals, Inc.
NASDAQRigel Pharmaceuticals heads into its May 14 earnings print with a freshly struck drug deal, a 12% pop on the session, and 21% of the float still held short. The catalyst was a licensing agreement with Arvinas and Pfizer for a PROTAC breast cancer compound, announced Tuesday. The deal gave shorts a rough day. Short interest fell about 6% on the week to roughly 22.9% of free float…
Snapshot as of 13 May 2026
Rigel Pharmaceuticals heads into its May 14 earnings print with a freshly struck drug deal, a 12% pop on the session, and 21% of the float still held short. The catalyst was a licensing agreement with Arvinas and…
Rigel Pharmaceuticals heads into its May 14 earnings report as one of the more heavily shorted small-cap biotechs in the market — and yesterday's 12% price jump has done nothing to ease the tension. Short sellers are…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RIGL — free to start on ORTEX.
Sign up for free →Open RIGL on ORTEX